JP6517702B2 - 脱分化したリプログラミングされた細胞から導出された細胞組成物 - Google Patents

脱分化したリプログラミングされた細胞から導出された細胞組成物 Download PDF

Info

Publication number
JP6517702B2
JP6517702B2 JP2015556262A JP2015556262A JP6517702B2 JP 6517702 B2 JP6517702 B2 JP 6517702B2 JP 2015556262 A JP2015556262 A JP 2015556262A JP 2015556262 A JP2015556262 A JP 2015556262A JP 6517702 B2 JP6517702 B2 JP 6517702B2
Authority
JP
Japan
Prior art keywords
cells
cell
endoderm
pluripotent
pdx1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015556262A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016506736A (ja
JP2016506736A5 (enExample
Inventor
アラン ディー． アグルニック、
アラン ディー． アグルニック、
オリビア ケリー、
オリビア ケリー、
ユキ オオイ
ユキ オオイ
アラン ロビンス、
アラン ロビンス、
トーマス シュルツ、
トーマス シュルツ、
Original Assignee
ヴィアサイト インコーポレイテッド
ヴィアサイト インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/761,078 external-priority patent/US9109245B2/en
Application filed by ヴィアサイト インコーポレイテッド, ヴィアサイト インコーポレイテッド filed Critical ヴィアサイト インコーポレイテッド
Publication of JP2016506736A publication Critical patent/JP2016506736A/ja
Publication of JP2016506736A5 publication Critical patent/JP2016506736A5/ja
Application granted granted Critical
Publication of JP6517702B2 publication Critical patent/JP6517702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0012—Cell encapsulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2015556262A 2013-02-06 2014-02-06 脱分化したリプログラミングされた細胞から導出された細胞組成物 Active JP6517702B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/761,078 2013-02-06
US13/761,078 US9109245B2 (en) 2009-04-22 2013-02-06 Cell compositions derived from dedifferentiated reprogrammed cells
PCT/US2014/015156 WO2014124172A1 (en) 2013-02-06 2014-02-06 Cell compositions derived from dedifferentiated reprogrammed cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019078983A Division JP6721752B2 (ja) 2013-02-06 2019-04-18 脱分化したリプログラミングされた細胞から導出された細胞組成物

Publications (3)

Publication Number Publication Date
JP2016506736A JP2016506736A (ja) 2016-03-07
JP2016506736A5 JP2016506736A5 (enExample) 2017-03-09
JP6517702B2 true JP6517702B2 (ja) 2019-05-22

Family

ID=50239931

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015556262A Active JP6517702B2 (ja) 2013-02-06 2014-02-06 脱分化したリプログラミングされた細胞から導出された細胞組成物
JP2019078983A Active JP6721752B2 (ja) 2013-02-06 2019-04-18 脱分化したリプログラミングされた細胞から導出された細胞組成物
JP2020104982A Active JP7250731B2 (ja) 2013-02-06 2020-06-18 脱分化したリプログラミングされた細胞から導出された細胞組成物
JP2022172222A Active JP7550830B2 (ja) 2013-02-06 2022-10-27 脱分化したリプログラミングされた細胞から導出された細胞組成物
JP2024151116A Pending JP2025000625A (ja) 2013-02-06 2024-09-03 脱分化したリプログラミングされた細胞から導出された細胞組成物

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019078983A Active JP6721752B2 (ja) 2013-02-06 2019-04-18 脱分化したリプログラミングされた細胞から導出された細胞組成物
JP2020104982A Active JP7250731B2 (ja) 2013-02-06 2020-06-18 脱分化したリプログラミングされた細胞から導出された細胞組成物
JP2022172222A Active JP7550830B2 (ja) 2013-02-06 2022-10-27 脱分化したリプログラミングされた細胞から導出された細胞組成物
JP2024151116A Pending JP2025000625A (ja) 2013-02-06 2024-09-03 脱分化したリプログラミングされた細胞から導出された細胞組成物

Country Status (8)

Country Link
EP (1) EP2954045A1 (enExample)
JP (5) JP6517702B2 (enExample)
AU (5) AU2014214879A1 (enExample)
CA (2) CA2898431C (enExample)
HK (1) HK1218139A1 (enExample)
IL (6) IL321825A (enExample)
RU (2) RU2754089C2 (enExample)
WO (1) WO2014124172A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9109245B2 (en) 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
SG11201700874SA (en) 2014-08-04 2017-03-30 Takeda Pharmaceuticals Co Method for proliferation of pancreatic progenitor cells
WO2017180361A1 (en) * 2016-04-14 2017-10-19 Janssen Biotech, Inc. Differentiation of pluripotent stem cells to intestinal midgut endoderm cells
EP3690022B1 (en) * 2016-05-18 2026-03-18 Keio University Cell culture medium for culturing organoid, culture method, and organoid
KR102448428B1 (ko) 2017-01-27 2022-09-30 가부시키가이샤 가네카 내배엽계 세포 집단, 및 다능성 세포로부터 3배엽 중 어느 하나의 세포 집단을 제조하는 방법
IL313825B2 (en) 2017-06-14 2025-07-01 Vertex Pharma Devices and methods for administering medications
JP2020527956A (ja) * 2017-07-21 2020-09-17 センマ・セラピューティクス・インコーポレーテッド 幹細胞由来の膵臓ベータ細胞の再凝集
WO2019169351A1 (en) 2018-03-02 2019-09-06 Semma Therapeutics, Inc. Methods of enhancing stem cell differentiation into beta cells
CN112912490B (zh) * 2018-08-03 2023-12-26 千纸鹤治疗公司 细胞制造方法
TWI862513B (zh) * 2018-09-19 2024-11-21 日商千紙鶴治療公司 包含胰島素產生細胞之細胞集團、包含該細胞集團之醫藥、其用途及製造方法
AU2020282355B2 (en) 2019-05-31 2023-11-02 Viacyte, Inc. A biocompatible membrane composite
US12310830B2 (en) 2019-05-31 2025-05-27 W. L. Gore & Associates, Inc. Biocompatible membrane composite
CA3257300A1 (en) 2019-05-31 2025-06-12 W. L. Gore & Associates, Inc. Cell encapsulation devices with controlled oxygen diffusion distances
EP3975926A1 (en) 2019-05-31 2022-04-06 W.L. Gore & Associates, Inc. A biocompatible membrane composite
JP7705448B2 (ja) 2020-07-31 2025-07-09 バーテックス ファーマシューティカルズ インコーポレイテッド 膵内分泌細胞の分化
EP4596675A4 (en) * 2022-09-26 2026-03-11 Univ Kyoto PROCESS FOR THE PRODUCTION OF PANCREATIC ENDODERMAL CELLS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4794049B2 (ja) * 1999-04-06 2011-10-12 ジェネンテック， インコーポレイテッド 糖尿病治療へのＥｒｂＢレセプターリガンドの使用
US6759039B2 (en) * 2000-06-30 2004-07-06 Amcyte, Inc. Culturing pancreatic stem cells having a specified, intermediate stage of development
CA2435826A1 (en) * 2001-01-24 2002-08-01 The Government Of The United States Of America Differentiation of stem cells to pancreatic endocrine cells
CA2625883A1 (en) * 2005-10-14 2007-04-26 Regents Of The University Of Minnesota Differentiation of non-embryonic stem cells to cells having a pancreatic phenotype
US20090298169A1 (en) * 2006-06-02 2009-12-03 The University Of Georgia Research Foundation Pancreatic and Liver Endoderm Cells and Tissue by Differentiation of Definitive Endoderm Cells Obtained from Human Embryonic Stems
EP2356227B1 (en) 2008-11-14 2018-03-28 Viacyte, Inc. Encapsulation of pancreatic cells derived from human pluripotent stem cells
ES2849181T3 (es) * 2009-04-22 2021-08-16 Viacyte Inc Composiciones celulares derivadas de células reprogramadas desdiferenciadas
US9109245B2 (en) * 2009-04-22 2015-08-18 Viacyte, Inc. Cell compositions derived from dedifferentiated reprogrammed cells
WO2010129294A2 (en) * 2009-04-27 2010-11-11 Schulz Thomas C Small molecules supporting pluripotent cell growth and methods thereof
EP2436397B1 (en) * 2009-05-29 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing antagonist of egf family ligand as component

Also Published As

Publication number Publication date
JP7550830B2 (ja) 2024-09-13
HK1218139A1 (zh) 2017-02-03
JP2020178694A (ja) 2020-11-05
CA2898431C (en) 2023-10-17
RU2018144412A3 (enExample) 2020-02-14
JP2016506736A (ja) 2016-03-07
IL311689A (en) 2024-05-01
JP2025000625A (ja) 2025-01-07
AU2023202507B2 (en) 2025-12-04
AU2014214879A1 (en) 2015-07-30
RU2015131279A (ru) 2017-03-13
WO2014124172A1 (en) 2014-08-14
IL326919A (en) 2026-05-01
JP2019146578A (ja) 2019-09-05
IL311689B2 (en) 2025-12-01
IL311689B1 (en) 2025-08-01
EP2954045A1 (en) 2015-12-16
AU2023202507A1 (en) 2023-05-11
IL283088A (en) 2021-06-30
IL239953A0 (en) 2015-08-31
AU2019201314B2 (en) 2021-10-14
IL239953B (en) 2021-05-31
JP7250731B2 (ja) 2023-04-03
RU2754089C2 (ru) 2021-08-26
JP6721752B2 (ja) 2020-07-15
IL290717A (en) 2022-04-01
CA3212301A1 (en) 2014-08-14
RU2675928C2 (ru) 2018-12-25
AU2026201562A1 (en) 2026-03-19
AU2019201314A1 (en) 2019-03-14
RU2018144412A (ru) 2019-03-25
JP2023017838A (ja) 2023-02-07
IL290717B2 (en) 2024-10-01
AU2022200075B2 (en) 2023-02-02
AU2022200075C1 (en) 2023-07-06
CA2898431A1 (en) 2014-08-14
IL290717B1 (en) 2024-06-01
IL283088B (en) 2022-04-01
AU2022200075A1 (en) 2022-02-03
IL321825A (en) 2025-08-01

Similar Documents

Publication Publication Date Title
JP7250731B2 (ja) 脱分化したリプログラミングされた細胞から導出された細胞組成物
JP7490035B2 (ja) 多能性幹細胞の膵臓内胚葉細胞（ＰＥＣ）および内分泌細胞へのｉｎ ｖｉｔｒｏ分化
EP2421957B1 (en) Cell compositions derived from dedifferentiated reprogrammed cells
RU2861299C2 (ru) Композиции клеток, полученных из дедифференцированных перепрограммированных клеток

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190326

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190418

R150 Certificate of patent or registration of utility model

Ref document number: 6517702

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250